The global traumatic brain injury therapeutics market is expected to exhibit strong growth, reaching USD 204.1 billion by 2030. As per the report titled "Traumatic brain injury therapeutics Market Size, Share & Recession Impact Analysis, By Treatment (Immediate Emergency Care, Medications, and Surgery), By Route of Administration (Parenteral and Oral), By Patient Age (Children, Teenager and Elder), By Gender (Male and Female), By Cause of Injury (Falls, Motor Vehicle Traffic, Sports and Others), By End Users (Hospitals, Neurology Clinics, Independent Pharmacies and Others), and Regional Forecasts, 2023-2030" observes that the market size in 2022 stood at USD 152.3 billion and USD 204.1 billion in 2030. The market is expected to exhibit a CAGR of 5.00% during the forecast period.
Arkansas Children's Hospital has Decided to Purchase TRIUX Neo for Functional Brain Imaging
In August 2021, Arkansas Children's Hospital accepts to purchase TRIUX Neo to imaging the functioning brain. When diagnosing individuals with a variety of conditions, such as epilepsy, brain tumours, traumatic brain injury, post-traumatic stress disorder, and autism, this will aid in the detecting capability.
Advancement of Technology in Medical Sector to Drive the Industry
Developments have significantly influenced the growth of the traumatic brain injury (TBI) treatments market in medical technology. Through the use of CT scans, MRI scans, and diffusion tensor imaging, advances in brain imaging technologies have improved the identification of traumatic brain injuries (TBIs). Moreover, neurostimulation techniques like deep brain stimulation and transcranial magnetic stimulation have the potential to help TBI patients recover more quickly from their cognitive and physical impairments by stimulating particular parts of the brain. Furthermore, by delivering medications directly to the injury site and reducing systemic adverse effects, advanced drug delivery devices, including implanted pumps and sustained-release formulations, have enhanced the efficacy and safety of TBI therapies.
Lack of Awareness Regarding TBI Therapeutics to Constrain Market Expansion
Traumatic brain injury (TBI) and its long-term effects remain little unknown, which might result in an underdiagnosis and undertreatment of the disorder. Many patients can wait until their symptoms are severe before seeking therapy, which can lead to a delayed diagnosis and worse consequences. The fact that TBI symptoms might be mild and may not be immediately obvious is one factor contributing to the lack of awareness of the condition. For instance, mild TBI patients may report headaches, lightheadedness, and weariness, which have various explanations. As a result, many patients could underestimate the importance of their symptoms and put off getting help. Public education and awareness initiatives about TBI and its effects are also lacking. The risk factors for TBI, like falls, car accidents, and sports-related injuries, may not be widely known. As a result, individuals might not take the necessary safety measures to avoid these injuries.
Major Players Develop Acquisition Plans to Boost Brand Image
The leading businesses in the traumatic brain injury therapeutics market plan acquisitions to improve their brand recognition globally. For instance, in January 2019, the U.S. FDA has submitted a request to Oculogica Inc. for permission to commercialize the EyeBOX device. During a 4-minute examination, this gadget uses eye-tracking to diagnose patients who may have suffered concussions.
List of Key Players Profiled in the Report
Arkansas Children's Hospital has Decided to Purchase TRIUX Neo for Functional Brain Imaging
In August 2021, Arkansas Children's Hospital accepts to purchase TRIUX Neo to imaging the functioning brain. When diagnosing individuals with a variety of conditions, such as epilepsy, brain tumours, traumatic brain injury, post-traumatic stress disorder, and autism, this will aid in the detecting capability.
Advancement of Technology in Medical Sector to Drive the Industry
Developments have significantly influenced the growth of the traumatic brain injury (TBI) treatments market in medical technology. Through the use of CT scans, MRI scans, and diffusion tensor imaging, advances in brain imaging technologies have improved the identification of traumatic brain injuries (TBIs). Moreover, neurostimulation techniques like deep brain stimulation and transcranial magnetic stimulation have the potential to help TBI patients recover more quickly from their cognitive and physical impairments by stimulating particular parts of the brain. Furthermore, by delivering medications directly to the injury site and reducing systemic adverse effects, advanced drug delivery devices, including implanted pumps and sustained-release formulations, have enhanced the efficacy and safety of TBI therapies.
Lack of Awareness Regarding TBI Therapeutics to Constrain Market Expansion
Traumatic brain injury (TBI) and its long-term effects remain little unknown, which might result in an underdiagnosis and undertreatment of the disorder. Many patients can wait until their symptoms are severe before seeking therapy, which can lead to a delayed diagnosis and worse consequences. The fact that TBI symptoms might be mild and may not be immediately obvious is one factor contributing to the lack of awareness of the condition. For instance, mild TBI patients may report headaches, lightheadedness, and weariness, which have various explanations. As a result, many patients could underestimate the importance of their symptoms and put off getting help. Public education and awareness initiatives about TBI and its effects are also lacking. The risk factors for TBI, like falls, car accidents, and sports-related injuries, may not be widely known. As a result, individuals might not take the necessary safety measures to avoid these injuries.
Major Players Develop Acquisition Plans to Boost Brand Image
The leading businesses in the traumatic brain injury therapeutics market plan acquisitions to improve their brand recognition globally. For instance, in January 2019, the U.S. FDA has submitted a request to Oculogica Inc. for permission to commercialize the EyeBOX device. During a 4-minute examination, this gadget uses eye-tracking to diagnose patients who may have suffered concussions.
List of Key Players Profiled in the Report
- Zimmer Biomet
- Neuren Pharmaceuticals
- Teva Pharmaceutical Industries Ltd
- Medicortex Finland Oy
- AMARANTUS BIOSCIENCE HOLDINGS, INC.
- Stemedica Cell Technologies, Inc.
- BANYAN BIOMARKERS, INC.
- BioDirection
- QuesGen Systems, Inc.
- Neural Analytics, Inc.
- Oculogica
- VASOPHARM
- Johnson & Johnson Services Inc.
- Smith & Nephew
- Stryker
- Medtronic
- Bioretec Ltd.
- B.Braun Melsungen AG
- Arthrex, Inc.
- Corin
- Orthofix Medical Inc.
- Acumed LLC
- Wright Medical Group N.V.
- NuVasive Inc.
- Advance Orthopaedic Solutions
- Arthrosurface
- CONMED Corporation
- Others
Further Report Findings
- The market in North America is expected to gain a huge portion of the global Traumatic brain injury therapeutics market share in the coming years due to extensive R&D by scientists at the U.S. Food and Drug Administration (FDA), an increase in fall-related cases, accidental cases, and other factors.
- In North America, the U.S. held the largest market share for the evaluation of traumatic brain injuries.
- In Asia Pacific, the growth in this region is primarily driven by the availability of cutting-edge medical innovation and the rising demand for TBI therapeutics.
| Attributes | Details |
| Market Size in 2022 | USD 569.5 Million |
| Market Forecast in 2030 | USD 1036.7 Million |
| Compound Annual Growth Rate | 10.50 % |
| Unit | Revenue (USD Million) and Volume (Kilo Tons) |
| Segmentation | By Treatment, By Route of Administration, By Patient Age, By Gender, By Cause of Injury, By End Users, and By Geography |
| By Treatment |
|
| By Route of Administration |
|
| By Patient Age |
|
| By Gender |
|
| By Cause of Injury |
|
| By End Users |
|
| By Region |
|
| Base Year | 2022 |
| Historical Year | 2016-2021 |
| Forecast Year | 2023-2030 |
